EP4694908A1 — Gastrointestinal retentive formulations of echinocandins
Assigned to Cleveland Clinic Foundation · Expires 2026-02-18 · 0y expired
What this patent protects
Provided herein are methods and compositions for delivering echinocandins (e.g., caspofungin) to a subject to increase retention time in the gastrointestinal tract (e.g., to promote a localized action in the intestinal region and reduced absorption of the echinocandin) after oral…
USPTO Abstract
Provided herein are methods and compositions for delivering echinocandins (e.g., caspofungin) to a subject to increase retention time in the gastrointestinal tract (e.g., to promote a localized action in the intestinal region and reduced absorption of the echinocandin) after oral administration of the composition. In certain embodiments, the compositions comprise an echinocandin and a carrier agent. In some embodiments, the compositions are used to treat fungal infections and/or inflammatory bowel disease in a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.